English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe issue was edited by Georgetown Lombardi’s Jeanne Mandelblatt, MD, MPH; Amy Trentham Dietz, PhD, professor of Population Health Sciences at the University of Wisconsin, Madison; and Rafael Meza, PhD, adjunct professor at the School of Population and Public Health at the University of British Columbia, Canada, and comprises articles by dozens of co-authors.
The studies in JNCI used modeling to synthesize data specifically for the overall U.S. population compared to the U.S. Black population to quantify the contributions of different aspects of cancer care to the impact on disparities in cancer mortality.
Given the high cost and long time periods needed to obtain results from clinical trials looking at interventions to prevent and treat many cancers and the chronic lack of sufficient enrollment of Black people in these trials, simulating cancer outcomes in diverse populations with sophisticated computer modeling tools is recommended by the National Academy of Sciences and others as a high-quality alternative assessment method. To that end, the Cancer Intervention and Surveillance Modeling Network (CISNET) has been funded by the National Cancer Institute, a part of the National Institutes of Health, since the year 2000 to advance modeling science for the disease.
The CISNET studies in this issue of JNCI considered an antiracism framework that aims to identify strategies to advance health equity among Black people and other populations underrepresented in medical research. The authors define health equity as “the absence of unfair, avoidable or remediable differences in health outcomes so that no one is disadvantaged by socioeconomics or other factors.”
“We have framed systemic racism as the root cause of inequity that can exert significant effects on cancer incidence and mortality and competing comorbidities,” says Mandelblatt, director of the Georgetown Lombardi Institute for Cancer and Aging Research as well as a professor of oncology and medicine at the Georgetown University School of Medicine. “Because of these research efforts, we hope that we have provided a framework to support the next generation of cancer population simulation models.”
Significantly, the researchers were able to confirm that CISNET modeled incidence and mortality rates closely matched observed cancer statistical trends over time, lending validity to the modeling approach.
The racial group-specific modeling in this issue is the first collaborative effort from virtually the entire CISNET Consortium addressing a single research question designed to identify leverage points that could be targeted to increase equity in cancer burden among Black populations. The resulting body of research illustrates how population simulation modeling can be applied to address critical public health issues.
Taken together, the results of the modeling analyses included several notable patterns:
- In cancers with widely used screening procedures but persistently large gaps in racial incidence, better access to screening by racial minorities could play a larger role in helping reduce those disparities.
- High-quality therapies (those in accordance with treatment recommendations from professional organizations with treatment guidelines delivered promptly after diagnosis, with all planned cycles completed and no or minimal dose reductions) could have a very positive impact on mortality disparities between Black people compared to the overall population, especially as new and more effective therapeutic options evolve.
The researchers hope that future models can better capture relationships between systemic racism and cancer outcomes and replace or extend single-level race variables with measures that capture structural, interpersonal, and internalized racism.
###
Mandelblatt reports having no personal financial interests related to these perspectives.
Research referenced in the perspectives was supported by National Cancer Institute grants U01 CA253911, U01 CA253858, R351CA 97289, R35CA283926, U01 CA199218 and P30CA014520 and a National Institute on Aging grant R21AG075008.
About Georgetown University’s Lombardi Comprehensive Cancer Center
Georgetown’s Lombardi Comprehensive Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington D.C. area. It serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi is also an NCI recognized consortium with John Theurer Cancer Center/Hackensack Meridian Health in Bergen County, New Jersey. The consortium reflects an integrated cancer research enterprise with scientists and physician-researchers from both locations. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational and clinical research, patient care, community education and outreach to service communities throughout the Washington region, while its consortium member John Theurer Cancer Center/Hackensack Meridian Health serves communities in northern New Jersey. Georgetown Lombardi is a member of the NCI Community Oncology Research Program (UG1CA239758). Georgetown Lombardi is supported in part by a National Cancer Institute Cancer Center Support Grant (P30CA051008). Connect with Georgetown Lombardi on Facebook (Facebook.com/GeorgetownLombardi) and Twitter (@LombardiCancer).
About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic health and science center with a four-part mission of research, teaching, service and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook (Facebook.com/GUMCUpdate) and Twitter (@gumedcenter).
